Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

A genome-wide Drosophila epithelial tumorigenesis screen identifies Tetraspanin 29Fb as an evolutionarily conserved suppressor of Ras-driven cancer.

Zoranovic T, Manent J, Willoughby L, Matos de Simoes R, La Marca JE, Golenkina S, Cuiping X, Gruber S, Angjeli B, Kanitz EE, Cronin SJF, Neely GG, Wernitznig A, Humbert PO, Simpson KJ, Mitsiades CS, Richardson HE, Penninger JM.

PLoS Genet. 2018 Oct 16;14(10):e1007688. doi: 10.1371/journal.pgen.1007688. eCollection 2018 Oct.

2.

An inhibitor of proteasome β2 sites sensitizes myeloma cells to immunoproteasome inhibitors.

Downey-Kopyscinski S, Daily EW, Gautier M, Bhatt A, Florea BI, Mitsiades CS, Richardson PG, Driessen C, Overkleeft HS, Kisselev AF.

Blood Adv. 2018 Oct 9;2(19):2443-2451. doi: 10.1182/bloodadvances.2018016360.

3.

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.

Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP.

Haematologica. 2018 Jul;103(7):1218-1228. doi: 10.3324/haematol.2017.174482. Epub 2018 Apr 5.

4.

Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.

Mahaweni NM, Bos GMJ, Mitsiades CS, Tilanus MGJ, Wieten L.

Cancer Immunol Immunother. 2018 Jun;67(6):861-872. doi: 10.1007/s00262-018-2140-1. Epub 2018 Mar 2.

5.

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J.

Br J Haematol. 2017 Dec;179(5):756-771. doi: 10.1111/bjh.14974. Epub 2017 Oct 19.

6.

The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma.

Le Moigne R, Aftab BT, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG 3rd, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M.

Mol Cancer Ther. 2017 Nov;16(11):2375-2386. doi: 10.1158/1535-7163.MCT-17-0233. Epub 2017 Sep 6.

7.

NF-κB dysregulation in multiple myeloma.

Matthews GM, de Matos Simoes R, Dhimolea E, Sheffer M, Gandolfi S, Dashevsky O, Sorrell JD, Mitsiades CS.

Semin Cancer Biol. 2016 Aug;39:68-76. doi: 10.1016/j.semcancer.2016.08.005. Epub 2016 Aug 17. Review.

PMID:
27544796
8.

Tight Junction Protein 1: New Insights into Proteasome Inhibitor Resistance and Myeloma Pathophysiology.

Mitsiades CS.

Cancer Cell. 2016 May 9;29(5):611-612. doi: 10.1016/j.ccell.2016.04.009.

9.

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.

Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG.

Br J Haematol. 2015 Jun;169(6):843-50. doi: 10.1111/bjh.13382.

PMID:
26032514
10.

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD.

Nat Med. 2015 Jun;21(6):572-80. doi: 10.1038/nm.3867. Epub 2015 May 25.

11.

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.

Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM.

Br J Haematol. 2015 Jun;169(6):851-8. doi: 10.1111/bjh.13383. Epub 2015 Apr 1.

12.

Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.

Mitsiades CS.

J Clin Oncol. 2015 Mar 1;33(7):782-5. doi: 10.1200/JCO.2014.55.5748. Epub 2015 Jan 20. No abstract available.

13.

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18261-6. doi: 10.1073/pnas.1421415111. Epub 2014 Dec 8.

14.

Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.

Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, Dastur A, Amzallag A, Ramaswamy S, Tesar B, Jenkins CE, Hannett NM, McMillin D, Sanda T, Sim T, Kim ND, Look T, Mitsiades CS, Weng AP, Brown JR, Benes CH, Marto JA, Young RA, Gray NS.

Nature. 2014 Jul 31;511(7511):616-20. doi: 10.1038/nature13393. Epub 2014 Jun 22.

15.

An epigenomic approach to therapy for tamoxifen-resistant breast cancer.

Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW.

Cell Res. 2014 Jul;24(7):809-19. doi: 10.1038/cr.2014.71. Epub 2014 May 30.

16.

Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.

Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS.

ACS Chem Biol. 2014 May 16;9(5):1086-91. doi: 10.1021/cb4008524. Epub 2014 Mar 17.

17.

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC.

Blood. 2014 Mar 6;123(10):1461-9. doi: 10.1182/blood-2013-07-517276. Epub 2014 Jan 15.

18.

Future agents and treatment directions in multiple myeloma.

Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC.

Expert Rev Hematol. 2014 Feb;7(1):127-41. doi: 10.1586/17474086.2014.858595. Epub 2013 Dec 18. Review.

19.

The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr.

Science. 2014 Jan 17;343(6168):305-9. doi: 10.1126/science.1244917. Epub 2013 Nov 29.

20.

A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice.

Hu Y, Zheng M, Gali R, Tian Z, Topal Görgün G, Munshi NC, Mitsiades CS, Anderson KC.

Blood Cancer J. 2013 Nov 1;3:e156. doi: 10.1038/bcj.2013.53.

21.

Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets.

Lawasut P, Groen RW, Dhimolea E, Richardson PG, Anderson KC, Mitsiades CS.

Semin Oncol. 2013 Oct;40(5):537-48. doi: 10.1053/j.seminoncol.2013.07.010. Review.

PMID:
24135398
22.

Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance.

de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N, Yuan H, Groen RW, McMillin DW, Jakubikova J, Lokhorst HM, Martens AC, Mitsiades CS, Mutis T.

Clin Cancer Res. 2013 Oct 15;19(20):5591-601. doi: 10.1158/1078-0432.CCR-12-3676. Epub 2013 Sep 4.

23.

Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma.

Mitsiades CS, Chen-Kiang S.

Crit Rev Oncol Hematol. 2013 Oct;88 Suppl 1:S5-13. doi: 10.1016/j.critrevonc.2013.05.014. Epub 2013 Jun 25. Review.

PMID:
23806982
24.

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P.

Cancer Chemother Pharmacol. 2013 May;71(5):1357-68. doi: 10.1007/s00280-013-2136-7. Epub 2013 Apr 16.

25.

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.

Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC.

Leuk Res. 2013 Jul;37(7):829-37. doi: 10.1016/j.leukres.2013.03.006. Epub 2013 Apr 9. Review.

PMID:
23582718
26.

The role of tumour-stromal interactions in modifying drug response: challenges and opportunities.

McMillin DW, Negri JM, Mitsiades CS.

Nat Rev Drug Discov. 2013 Mar;12(3):217-28. doi: 10.1038/nrd3870. Review.

PMID:
23449307
27.

High-throughput approaches to discover novel immunomodulatory agents for cancer.

McMillin DW, Mitsiades CS.

Oncoimmunology. 2012 Nov 1;1(8):1406-1408.

28.

Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ.

Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL.

J Breast Cancer. 2012 Sep;15(3):273-82. doi: 10.4048/jbc.2012.15.3.273. Epub 2012 Sep 28.

29.

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.

Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS.

Br J Haematol. 2012 Nov;159(3):340-51. doi: 10.1111/j.1365-2141.2012.09253.x. Epub 2012 Sep 13.

30.

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC.

Cancer Manag Res. 2012;4:253-68. doi: 10.2147/CMAR.S27087. Epub 2012 Aug 14.

31.

H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia.

Kawahara M, Pandolfi A, Bartholdy B, Barreyro L, Will B, Roth M, Okoye-Okafor UC, Todorova TI, Figueroa ME, Melnick A, Mitsiades CS, Steidl U.

Cancer Cell. 2012 Aug 14;22(2):194-208. doi: 10.1016/j.ccr.2012.06.027.

32.

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC.

Blood. 2012 Dec 13;120(25):5002-13. doi: 10.1182/blood-2011-07-368142. Epub 2012 Jul 20.

33.

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U.

Blood. 2012 Aug 9;120(6):1290-8. doi: 10.1182/blood-2012-01-404699. Epub 2012 Jun 21.

34.

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Blood. 2012 Jul 12;120(2):386-94. doi: 10.1182/blood-2011-12-399667. Epub 2012 May 24.

35.

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC.

Br J Haematol. 2012 Jun;157(6):718-31. doi: 10.1111/j.1365-2141.2012.09120.x. Epub 2012 Apr 26.

36.

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.

Rickles RJ, Tam WF, Giordano TP 3rd, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS.

Mol Cancer Ther. 2012 Jul;11(7):1432-42. doi: 10.1158/1535-7163.MCT-11-0925. Epub 2012 Apr 3.

37.

Inhibition of tumor cells interacting with stromal cells by xanthones isolated from a Costa Rican Penicillium sp.

Cao S, McMillin DW, Tamayo G, Delmore J, Mitsiades CS, Clardy J.

J Nat Prod. 2012 Apr 27;75(4):793-7. doi: 10.1021/np2009863. Epub 2012 Mar 29.

38.

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

McMillin DW, Delmore J, Negri JM, Vanneman M, Koyama S, Schlossman RL, Munshi NC, Laubach J, Richardson PG, Dranoff G, Anderson KC, Mitsiades CS.

Blood. 2012 Apr 12;119(15):e131-8. doi: 10.1182/blood-2011-04-348490. Epub 2012 Jan 30.

39.

Management of myeloma-associated renal dysfunction in the era of novel therapies.

Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG.

Expert Rev Hematol. 2012 Feb;5(1):51-66; quiz 67-8. doi: 10.1586/ehm.11.72. Review.

PMID:
22272706
40.

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, Yu J, Smith PG, Richardson PG, Anderson KC, Treon SP, Kung AL, Mitsiades CS.

Mol Cancer Ther. 2012 Apr;11(4):942-51. doi: 10.1158/1535-7163.MCT-11-0563. Epub 2012 Jan 12.

41.

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A.

Science. 2011 Nov 25;334(6059):1129-33. doi: 10.1126/science.1206727. Epub 2011 Oct 27.

42.

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.

Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC.

Eur J Haematol. 2012 Jan;88(1):1-7. doi: 10.1111/j.1600-0609.2011.01721.x. Epub 2011 Nov 22. Review.

43.

Management of relapsed and relapsed/refractory multiple myeloma.

Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG.

J Natl Compr Canc Netw. 2011 Oct;9(10):1209-16.

PMID:
21975917
44.

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS.

Cell. 2011 Sep 16;146(6):904-17. doi: 10.1016/j.cell.2011.08.017. Epub 2011 Sep 1.

45.

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.

Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC.

Oncology (Williston Park). 2011 Jun;25(7):594, 596. Review. No abstract available.

46.

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.

McMillin DW, Delmore J, Negri J, Ooi M, Klippel S, Miduturu CV, Gray NS, Richardson PG, Anderson KC, Kung AL, Mitsiades CS.

PLoS One. 2011;6(7):e20226. doi: 10.1371/journal.pone.0020226. Epub 2011 Jul 7.

47.

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.

Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, Chauhan D, Ghobrial IM, Munshi N, Anderson KC.

Br J Haematol. 2011 Sep;154(6):755-62. doi: 10.1111/j.1365-2141.2011.08791.x. Epub 2011 Jul 7. Review.

PMID:
21732930
48.

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.

Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin DW, Hideshima T, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS.

Haematologica. 2011 Aug;96(8):1170-9. doi: 10.3324/haematol.2010.029363. Epub 2011 Jun 28.

49.

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG.

J Clin Oncol. 2011 May 10;29(14):1916-23. doi: 10.1200/JCO.2010.34.0760. Epub 2011 Apr 11. Review.

PMID:
21482978
50.

Tanespimycin as antitumor therapy.

Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):17-22. doi: 10.3816/CLML.2011.n.002. Review.

PMID:
21454186

Supplemental Content

Loading ...
Support Center